Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
In Reply: Dr Fukuda and colleagues question
whether the effect of the BP intervention was greater for patients randomized
to amlodipine than for patients assigned to ramipril or metoprolol. There
was no significant relationship between the effect of the BP intervention
and the antihypertensive drug group for the primary outcome of GFR slope or
the main secondary clinical composite outcome comprising GFR events, end-stage
renal disease, or death (P values for the BP by drug
group interaction were .64, .61, and .18 for the chronic slope, total slope,
and clinical composite outcomes, respectively). Thus, in accordance with the
study design, our primary article addressed the overall BP comparison combining
the 3 drug groups. Separate comparisons of the BP goals within the individual
drug groups will be provided in subsequent publications.
Greene T, Appel LJ, Agodoa LY, Wright, Jr JT, for the AASK Study Group . Estrogen Replacement and Risk of Alzheimer Disease—Reply. JAMA. 2003;289(9):1102-1103. doi:10.1001/jama.289.9.1102-a